Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20247436 | 0.85 | CHRNB2 (0.42) | MCHR1HTTCHRNB2CHRNA4CHRNA6 | |
| SCHEMBL1563915 | 0.81 | MCHR1 (0.48) | MCHR1HTTCHRNB2CHRNA4IDO1 | |
| SCHEMBL12893078 | 0.80 | CHRNB2 (0.47) | MCHR1CHRNB2CHRNA4CHRNA6TLR8 | |
| 1,2-Diisopentoxybenzene SCHEMBL2843498 | 0.77 | HTT (0.62) | MCHR1HTTIDO1TLR8TDP1 | |
| SCHEMBL19368174 | 0.77 | L3MBTL1 (0.58) | MCHR1HTTIDO1TLR8TDP1 | |
| SCHEMBL3433200 | 0.77 | KDM4E (0.55) | CHRNB2CHRNA4CHRNA6TDP1MEN1 | |
| SCHEMBL18833817 | 0.76 | CHRNB2 (0.49) | HTTCHRNB2CHRNA4CHRNA6TDP1 | |
| SCHEMBL13533392 | 0.76 | TLR8 (0.47) | MCHR1TLR8 | |
| SCHEMBL4807186 | 0.75 | HTR1B (0.47) | CHRNB2CHRNA4CHRNA6TDP1MEN1 | |
| SCHEMBL20247449 | 0.75 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA6TDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252605-B1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INST NAT SANTE RECH MED (FR) | 2018-06-13 | — | — | EP | disclosed |
| US-9125937-B2 | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044899-A1 | LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS | CBR3, ADRB3, HRH4 | MCHR1 311/4885HTT 1391/4885CHRNB2 664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.